Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CSP Introduces Activ-Blister® Technology for Pharmaceutical Manufacturers

Published: Monday, October 22, 2012
Last Updated: Monday, October 22, 2012
Bookmark and Share
Innovative desiccated blister packaging protects moisture and oxygen-sensitive solid dose pharmaceuticals for better product performance.

CSP Technologies has announced the global launch of its Activ-Blister® desiccated blister packaging for the pharmaceutical industry.

Activ-Blister® desiccant film technology controls the internal atmosphere of each individual blister cavity, protecting moisture and oxygen-sensitive solid dose pharmaceuticals.

The result is optimized product stability, increased shelf-life, and greater consumer convenience.

Activ-Blister® also helps ensure consumer safety, because unlike conventional desiccants, there is no chance of accidental ingestion.

Activ-Blister® offers manufacturers superior flexibility in packaging design, providing an opportunity to differentiate their products.

By eliminating the need for traditional desiccant tablets in separate blister wells, Activ-Blister® allows for a slimmer, more convenient packaging form-factor while simplifying the end-user experience.

In addition, by featuring product protection without increased blister size, Activ-Blister® provides manufacturers with potential cost savings through reduced material usage, freight costs and fuel consumption.

“Activ-Blister® is an entirely new approach to protecting pharmaceuticals with specialized packaging that can build a unique identity for brands,” according to Dan L’Ecuyer, Vice President of Sales & Marketing at CSP Technologies.

L’Ecuyer continued, “Rather than use a desiccant chip inside a separate well in a blister, our proven technologies provides all the protection without increasing blister size and material or shipping costs.”

CSP’s patented technology integrates precise desiccant, gas-absorption, and sealing properties into the blister-pack itself, extending shelf life and product performance.

Activ-Blister® exhibits excellent performance capacity with moisture absorption up to 20mgs and oxygen scavenging up to 30ccs.

In addition, CSP’s Activ-Blister®® technology is available in a variety of sizes, including all type of round tablets and capsules up to size 0, with either multilayer barrier films or aluminum foil blisters to provide protection from both moisture and oxygen.

“Safely preserving drug potency and extending shelf life are high priorities for pharmaceutical manufacturers, and for the patients who rely on their products,” says L’Ecuyer.

“Activ-Blister®, CSP’s breakthrough solid dose packaging technology provides a strong product solution that meets customer needs while also safeguarding patient health.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
Safer, Cheaper, Greener and More Efficient System for Organic Synthesis
The new medium not only supports organic synthesis it also produces considerably higher yields of product than pure organic solvents.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Collaboration to Develop Cancer Therapeutics
Major license agreement with Merck, enabled by Blavatnik Biomedical Accelerator, aims to develop therapy for most common form of acute leukemia.
Faster UVA Molecular Analysis Technology
There are people in the world – chemical engineers, astronomers, national defense scientists investigating an explosion – who need to know just what something is made of, down to the molecular level.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!